Chew NW, Chong B, Kuo SM, Jayabaskaran J, Cai M, Zheng H et al (2023) Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohort. The Lancet Regional Health. https://doi.org/10.1016/j.lanwpc.2023.100803

Article  PubMed  PubMed Central  Google Scholar 

Chew NW, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, et al (2023) The global burden of metabolic disease: data from 2000 to 2019. Cell Metabolism 35(3):414–28.e3

Chong B, Jayabaskaran J, Jauhari SM, Chia J, Le Roux CW, Mehta A et al (2025) The global syndemic of modifiable cardiovascular risk factors projected from 2025 to 2050. J Am Coll Cardiol 86(3):165–177

Article  PubMed  PubMed Central  Google Scholar 

Kong G, Chin YH, Chong B, Goh RSJ, Lim OZH, Ng CH et al (2023) Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: results from a global meta-analysis of 1,285,722 patients. Int J Cardiol 371:432–440

Article  PubMed  Google Scholar 

Chew NW, Mehta A, Goh R, Koh J, Chen Y, Chong B et al (2025) The global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges. Nat Rev Cardiol. https://doi.org/10.1038/s41569-025-01220-4

Article  PubMed  Google Scholar 

Goh RSJ, Koh J, Utami Intaran MA, Chin Y, Kong G, Chong B et al (2025) Population‐based study on the coexistence of metabolic dysfunction‐associated steatotic liver disease and chronic kidney disease. J Am Heart Assoc 14(19):e041834

Article  PubMed  PubMed Central  Google Scholar 

Al-Jarshawi M, Chew N, Bonaca MP, Ray KK, Mamas MA (2026) The additive prognostic value of lipoprotein (a) for all-cause and cardiovascular mortality across the traditional cardiovascular risk continuum: analysis from NHANES III (1988–1994) with follow-up to 2019. Eur J Prev Cardiol. zwag037. Epub ahead of print

Hanif M, Khan LA, Kulkarni A, Bhatia HS, Wilkinson MJ, Rashid AM et al (2025) Global lipoprotein (a) testing trends from 2015 to 2023. Am Heart J 289:171–179

Article  CAS  PubMed  Google Scholar 

Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS et al (2023) Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148(20):1606–1635

Article  PubMed  Google Scholar 

Chen Y, Himan HR, Yazicioglu Y, Goh R, Chin YH, Chong B et al (2026) Population estimates, trends, characteristics and prognostic outcomes of cardiovascular-kidney-liver-metabolic health: a population-based study. Am J Prev Cardiol. https://doi.org/10.1016/j.ajpc.2025.101405

Article  PubMed  PubMed Central  Google Scholar 

Miyamori D, Tanaka M, Sato T, Endo K, Mori K, Mikami T et al (2023) Coexistence of metabolic dysfunction‐associated fatty liver disease and chronic kidney disease is a more potent risk factor for ischemic heart disease. J Am Heart Assoc 12(14):e030269

Article  PubMed  PubMed Central  Google Scholar 

Consortium CKDP (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375(9731):2073–2081

Article  Google Scholar 

News AHA (2023) New tool brings big changes to cardiovascular disease predictions. Available from: https://www.heart.org/en/news/2023/11/10/new-tool-brings-big-changes-to-cardiovascular-disease-predictions. Accessed 10 Feb 2024

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78(6):1966–1986

Article  PubMed  PubMed Central  Google Scholar 

Chan KE, Ong EYH, Chung CH, Ong CEY, Koh B, Tan DJH, et al (2023) Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies. Clin Gastroenterol Hepatol 22(3):488-498.e41

Chew NW, Mehta A, Goh RSJ, Zhang A, Chen Y, Chong B et al (2025) Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach. Circulation 151(1):98–119

Article  PubMed  Google Scholar 

Moon JH, Jeong S, Jang H, Koo BK, Kim W (2023) Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinMed. https://doi.org/10.1016/j.eclinm.2023.102292

Article  Google Scholar 

Lee EC, Anand VV, Razavi AC, Alebna PL, Muthiah MD, Siddiqui MS et al (2024) The global epidemic of metabolic fatty liver disease. Curr Cardiol Rep 26(4):199–210

Article  PubMed  Google Scholar 

Chew NW, Pan XH, Chong B, Chandramouli C, Muthiah M, Lam CS (2024) Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population. Diabetes Res Clin Pract 211:111652

Article  CAS  PubMed  Google Scholar 

Chew NW, Chong B, Ng CH, Kong G, Chin YH, Xiao W et al (2022) The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Front Genet 13:971484

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anand VV, Zhe ELC, Chin YH, Lim WH, Goh RSJ, Lin C et al (2023) Barriers and facilitators to engagement with a weight management intervention in Asian patients with overweight or obesity: a systematic review. Endocr Pract 29(5):398–407

Article  PubMed  Google Scholar 

Chin Y, Lim J, Kong G, Ng CH, Goh R, Muthiah M et al (2023) Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction. Diabetes Obes Metab 25(4):1032–1044

Article  CAS  PubMed  Google Scholar 

Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J et al (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67(6):2089–2100

Article  PubMed  Google Scholar 

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO (2024) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105(4S):S117–S314. https://doi.org/10.1016/j.kint.2023.10.018

Article  Google Scholar 

Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612

Article  PubMed  PubMed Central  Google Scholar 

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F, et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78(6):1966-1986

WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363(9403):157–163. https://doi.org/10.1016/S0140-6736(03)15268-3

Article  Google Scholar 

Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS (2019) Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol 73(8):948–963

Article  PubMed  Google Scholar 

Lee J-H, Kim D, Kim HJ, Lee C-H, Yang JI, Kim W et al (2010) Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42(7):503–508

Article  CAS  PubMed  Google Scholar 

Kong G, Cao G, Koh J, Chan SP, Zhang A, Wong E, et al (2024) The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: a propensity score‐matched analysis. Diabetes Obes Metab 26(8):3328-3338

Chew NW, Figtree GA, Kong G, Vernon S, Muthiah M, Ng CH et al (2022) Hepatic steatosis and advanced fibrosis are independent predictors of mortality in acute myocardial infarction without standard modifiable risk factors. Diabetes Obes Metab 24(12):2454–2458

Article  CAS  PubMed  Google Scholar 

Araújo SP, Juvanhol LL, Bressan J, Hermsdorff HHM (2022) Triglyceride glucose index: a new biomarker in predicting cardiovascular risk. Prev Med Rep 29:101941

Article  PubMed  PubMed Central  Google Scholar 

Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J et al (2017) The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis 16:1–8

Article  PubMed  PubMed Central  Google Scholar 

Zheng R, Du Z, Wang M, Mao Y, Mao W (2018) A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis 17:1–9

Article  CAS  Google Scholar 

Ampuero J, Aller R, Gallego‐Durán R, Banales JM, Crespo J, García‐Monzón C et al (2018) The effects of metabolic status on non‐alcoholic fatty liver disease‐related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther 48(11–12):1260–1270

Article  CAS  PubMed  Google Scholar 

Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43(6):1317–1325

Article  CAS  PubMed